Key Takeaways
- Commercialization should begin as strategic thinking well before commercial infrastructure is built.
- First-launch biotechnology companies need longer preparation because commercial capabilities must often be created from zero.
- Market access, evidence, organization and commercial strategy should develop together.
- Early commercial planning improves both launch readiness and strategic optionality.
One of the questions emerging biotechnology leaders frequently confront is deceptively simple:
When should we begin preparing for commercialization?
The conventional answer is often tied to a clinical or regulatory milestone—Phase III, NDA submission, or FDA approval.
In my experience, that framing misses the larger issue.
Commercialization is not an event that begins when a commercial organization is hired. It is the culmination of decisions made throughout development.
The better question is therefore:
Which commercial decisions must be made now because waiting will reduce our options later?
Commercial Thinking Should Begin Before Commercial Infrastructure
Starting commercial planning early does not mean hiring an entire commercial organization years before launch.
It means introducing commercial thinking into development decisions.
A biotechnology company in Phase II may not need a sales organization. It may, however, already need to understand the real diagnosed patient population, where patients are treated, diagnostic barriers, referral pathways, Centers of Excellence, emerging competitors, evidence gaps, payer considerations, potential distribution requirements and future patient-support needs.
These questions influence decisions being made today. For emerging biotechnology companies, that work is part of biotech commercialization consulting—not a late-stage marketing exercise.
Phase II: Understand the Market
During Phase II, commercial planning should focus heavily on learning.
Leadership should challenge epidemiological assumptions and begin understanding the actual treatment ecosystem. A disease may affect tens of thousands of people while only a fraction are diagnosed, actively treated or accessible through the expected treatment network.
The commercial opportunity is therefore rarely represented by prevalence alone.
Leadership should begin asking: Who diagnoses these patients? Who treats them? Where do they receive care? How long does diagnosis take? Where are patients lost? What determines referral? Which institutions influence treatment? What evidence could change physician behavior?
This work can influence clinical development and evidence-generation strategy.
Phase III: Convert Understanding Into Decisions
As the asset progresses, commercial planning must become increasingly operational.
Leadership may need to decide commercialization model, organizational structure, leadership requirements, hiring sequence, Market Access capabilities, Medical Affairs expansion, patient services, distribution, field strategy and launch governance.
The central objective is to avoid discovering eighteen months before launch that a capability requires three years to build. That is why a structured launch readiness assessment becomes valuable as pivotal development advances.
The First Launch Is Different
Established pharmaceutical companies already possess commercial infrastructure. Emerging biotechnology companies often do not.
A first launch may require building capabilities across Commercial, Medical Affairs, Market Access, commercial operations, patient services, analytics, compliance, training, distribution and supply chain.
This means first-launch companies generally need to think further ahead. PharmaKonsult’s first commercial launch advisory is built around that organizational transformation.
Commercial Planning Protects Strategic Optionality
Early commercialization planning creates another advantage: better information when evaluating strategic alternatives.
Should the company commercialize independently? Partner? License the asset? Seek acquisition? Raise additional capital?
Without understanding the real commercialization requirements, those decisions are being made with incomplete information.
Start With Questions, Not Headcount
The goal of early commercial planning is not premature organizational expansion. It is better decision-making.
Start by understanding the disease, patients, physicians, institutions, access environment and commercial requirements. Build capabilities as the strategy becomes clearer.
The strongest commercial organizations are not necessarily those that start spending earliest. They are those that start thinking earliest.
Preparing for Commercialization?
PharmaKonsult helps emerging biotechnology leadership teams understand what commercialization will require long before launch decisions become difficult to change.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
